Kanwal P.S. Raghav, MBBS, MD

Peer-Reviewed Articles

1. Malpica A, Euscher ED, Marques-Piubelli ML, Ferrufino-Schmidt MC, Miranda RN, Sams R, Royal RE, Raghav KPS, Fournier KF, Ramalingam P. Malignant Mesothelioma of the Peritoneum in Women: A Clinicopathologic Study of 164 Cases. Am J Surg Pathol 45(1):45-58, 2021. e-Pub 2020. PMID: 32769428.
2. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol 17(12):757-770, 2020. e-Pub 2020. PMID: 32632268.
3. Raghav K, Overman M, Poage GM, Soifer HS, Schnabel CA, Varadhachary GR. Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay. Oncologist 25(11):e1807-e1811, 2020. e-Pub 2020. PMID: 32893931.
4. Raghav K, Shen JP, Jácome AA, Guerra JL, Scally CP, Taggart MW, Foo WC, Matamoros A, Shaw KR, Fournier K, Overman MJ, Eng C. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br J Cancer 123(8):1262-1270, 2020. e-Pub 2020. PMID: 32733093.
5. Chu JE, Johnson B, Kugathasan L, Morris VK, Raghav K, Swanson L, Lim HJ, Renouf DJ, Gill S, Wolber R, Karsan A, Kopetz S, Schaeffer DF, Loree JM. Population-based screening for BRAFV600E in metastatic colorectal cancer reveals increased prevalence and poor prognosis. Clin Cancer Res 26(17):4599-4605, 2020. e-Pub 2020. PMID: 32571791.
6. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. PMID: 32188704.
7. Huey RW, Makawita S, Xiao L, Matamoros A, Estrella JS, Overman MJ, Varadhachary GR, Raghav K. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. BMC Cancer 19(1):965, 2019. e-Pub 2019. PMID: 31623602.
8. Pedersen KS, Raghav K, Overman MJ. Small Bowel Adenocarcinoma: Etiology, Presentation, and Molecular Alterations. J Natl Compr Canc Netw 17(9):1135-1141, 2019. PMID: 31487680.
9. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol 5(6):824-830, 2019. e-Pub 2019. PMID: 30998813.
10. Siravegna G, Sartore-Bianchi A, Nagy RJ, Raghav K, Odegaard JI, Lanman RB, Trusolino L, Marsoni S, Siena S, Bardelli A. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res 25(10):3046-3053, 2019. e-Pub 2019. PMID: 30808777.
11. Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin Cancer Res 25(7):2033-2041, 2019. e-Pub 2018. PMID: 30442682.
12. Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 20(4):518-530, 2019. e-Pub 2019. PMID: 30857956.
13. 53. Raghav K, Loree JM, Morris JS, Overman MJ, Yu Ruoxi, Meric-Bernsatm F, Menter D, Korphaisarn K, Kee B, Muranyi A, Singh S, Routbourt M, Chen K, Shaw KR, Katkhuda R, Shanmugam K, Maru D, Fakih M, Kopetz S.. Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019. e-Pub 2019.
14. Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D. Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev 66:95-103, 2018. e-Pub 2018. PMID: 29730462.
15. Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol 33(31):3583-90, 2015. e-Pub 2015. PMID: 26304898.
16. Shah MS, Fogelman DR, Raghav KP, Heymach JV, Tran HT, Jiang ZQ, Kopetz S, Daniel CR. Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. Cancer 121(17):2968-75, 2015. e-Pub 2015. PMID: 25975416.
17. Abdel-Wahab R, Shehata S, Hassan MM, Xiao L, Lee JS, Cheung S, Essa HH, Hassabo HM, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, Kaseb AO. Validation of an IGF-CTP Scoring System for Assessing Hepatic Reserve in Egyptian Patients with Hepatocellular Carcinoma. Oncotarget 6(25):21193-207, 2015. PMID: 26098859.
18. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112(6):1088-97, 2015. e-Pub 2015. PMID: 25688736.
19. Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst 106(5), 2014. e-Pub 2014. PMID: 24815863.
20. Raghav K, Overman MJ. Small bowel adenocarcinomas-existing evidence and evolving paradigms. Nat Rev Clin Oncol 10(9):534-44, 2013. e-Pub 2013. PMID: 23897080.
21. Raghav KP, Shetty AV, Kazmi SM, Zhang N, Morris J, Taggart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff RA, Overman MJ. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist 18(12):1270-7, 2013. e-Pub 2013. PMID: 24149137.
22. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18(8):2269-77, 2012. e-Pub 2012. PMID: 22374333.
23. Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118(6):1498-506, 2012. e-Pub 2011. PMID: 21837669.
24. Raghav KP, Makkuni P, Figueredo VM. A review of electrocardiography in pulmonary embolism: recognizing pulmonary embolus masquerading as ST-elevation myocardial infarction. Rev Cardiovasc Med 12(3):157-63, 2011. PMID: 22145193.
25. Zhao Y, Pan Z, Namburi S, Pattison A, Posner A, Balachander S, Paisie CA, Reddi HV, Rueter J, Gill AJ, Fox S, Raghav KPS, Flynn WF, Tothill RW, Li S, Karuturi RKM, George J. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. EBioMedicine 61:103030. e-Pub 2020. PMID: 33039710.
26. Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncol:e191870. e-Pub 2019. PMID: 31415071.
27. Raghav K, Strickler JH. The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. JAMA Oncol. e-Pub 2019. PMID: 31415062.
28. Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. e-Pub 2019. PMID: 30854646.
29. Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, Davis JS, Shaw KR, Broaddus R, Banks KC, Lanman RB, Meric-Bernstam F, Overman MJ, Kopetz S, Raghav K. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst. e-Pub 2018. PMID: 29718453.

Invited Articles

1. Raghav KPS. The role of HER2 amplification testing in metastatic colorectal cancer. Clin Adv Hematol Oncol 16(11):720-722, 2018. PMID: 30543586.
2. Raghav KP, Gonzalez-Angulo AM, Blumenschein GR. Role of HGF/MET axis in resistance of lung cancer to contemporary management. Translational Lung Cancer Research 1(2):179-193, 2012.
3. Raghav KP, Eng C. Role of MET/HGF Axis in Colorectal Cancer: Precepts and Prospects. Colorectal Cancer 1(4):329-341, 2012.
4. Raghav KP, Blumenschein GR. Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs 20(6):859-69, 2011. e-Pub 2011. PMID: 21534718.

Manuals, Teaching Aids, Other Teaching Publications

1. Raghav KP. NEJM Knowledge+. The New England Journal of Medicine, 2014.

Other Articles

1. Pande SA, Raghav K, Mehta S, Babbar G, Kandpal S A woman with a swollen uvula. Cleve Clin J Med 79(9):600-1, 2012. PMID: 22949339.

Editorials

1. Raghav KP, Gonzalez-Angulo AM. Commentary on: Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Breast Diseases: A Year Book Quarterly 22(2):156-158, 2011.

Abstracts

1. Raghav KP, Mhadgut H, Lei X, Overman MJ, Ross A, Renato L, Raber M, Varadhacahry GR. Cancer of unknown primary in adolescents and young adults: Clinicopathologic features, prognostic factors, and survival outcomes. ASCO Annual Meeting 2014, 2014.
2. Raghav KP, Amin HM, Wang W, Manyam GC, Broom B, Eng C, Overman MJ, Kopetz S. MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. ASCO Annual Meeting 2013, 2013.
3. Raghav KP, Amin HM, Wang W, Manyam GC, Broom B, Eng C, Overman MJ, Kopetz S. MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. Gastrointestinal Cancer Symposium 2013, 2013.
4. Raghav KP, Kalil K, Ferrarotto R, George B, Eng C, Garrett C, Loyer EM, Hoff PM, Charnsangavej C, Kopetz S, Overman MJ. Bevacizumab reduces the rate of oxaliplatin induced thrombocytopenia and splenomegaly. ASCO Annual Meeting 2012, 2012.
5. Raghav KP, Kazmi SMA, Shetty AV, Taggart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff RA, Overman MJ. Uncovering the clinicopathological and mutational profile of appendiceal adenocarcinomas. Gastrointestinal Cancer Symposium 2012, 2012.
6. Raghav KP, Kalil K, Ferrarotto R, George B, Eng C, Garrett C, Loyer EM, Hoff PM, Charnsangavej C, Kopetz S, Overman MJ. Bevacizumab reduces the rate of oxaliplatin induced thrombocytopenia and splenomegaly. Gastrointestinal Cancer Symposium 2012, 2012.
7. Raghav KP, Wang W, Liu S, Chavez-Mac Gregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein Jr. GR, Gonzalez-Angulo AM. Expression of cMET and phospho-cMET in breast cancers by subtype and impact on survival outcomes. AACR San Antonio Breast Cancer Symposium 2011, 2011.
8. Raghav KP, Liu DD, Matrana MR, Bekele BN, Valero V, Ibrahim NK. Nomogram for predicting development of brain metastasis in patients with inflammatory breast cancer. ASCO Breast Cancer Symposium 2011, 2011.

Book Chapters

1. Raghav KP, Raber M, Varadhachary GR. Cancer of Unknown Primary Site. In: Clinical Decision Support: ONCOLOGY, 2015.
2. Raghav KP, Varadhachary GR. Favorable Subsets Among Cancers of Unknown Primary. In: Textbook of carcinoma of unknown primary. 1. Springer publishing house: Heidelberg, Germany, 2015.
3. Raghav KP, Gilbert MR. Ependymomas. In: Neuro-oncology. First. Blackwell Publishing Ltd: Oxford, UK, 86-94, 2012.
4. Raghav KP, Katz MH, Overman MJ. Cancers of the Small Bowel. In: Textbook of Uncommon Cancer. Fourth. John Wiley & Sons, Inc: Hoboken, NJ, USA, 4441-451, 2012.

Letters to the Editor

1. Overman MJ, Eng C, Raghav K, Matamoros A, Taggart M, Foo WC, Fournier K. Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist 20: e3-4, 2015.
2. Raghav KP, Taggart MW, Fournier KF, Overman MJ. Is malignant dedifferentiation for mucinous appendiceal neoplasms a valid phenomenon or merely histopathologic ambiguity?. J Am Coll Surg 212: 906; author reply 907, 2011.